Algert Global LLC Has $5.50 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

Algert Global LLC grew its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,713 shares of the company's stock after purchasing an additional 13,696 shares during the quarter. Algert Global LLC owned approximately 0.22% of LivaNova worth $5,498,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of LIVN. Russell Investments Group Ltd. boosted its holdings in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after acquiring an additional 219 shares during the period. Summit Investment Advisors Inc. increased its position in LivaNova by 1.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock worth $780,000 after buying an additional 289 shares during the period. Xponance Inc. lifted its holdings in shares of LivaNova by 6.1% during the fourth quarter. Xponance Inc. now owns 7,762 shares of the company's stock worth $359,000 after buying an additional 445 shares during the last quarter. Mariner LLC grew its stake in shares of LivaNova by 8.4% in the fourth quarter. Mariner LLC now owns 5,741 shares of the company's stock worth $266,000 after acquiring an additional 446 shares during the last quarter. Finally, Invesco Ltd. raised its stake in LivaNova by 0.6% during the 4th quarter. Invesco Ltd. now owns 111,374 shares of the company's stock valued at $5,158,000 after purchasing an additional 667 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Price Performance

LIVN stock traded down $0.01 during midday trading on Friday, reaching $44.06. 1,063,416 shares of the company's stock traded hands, compared to its average volume of 637,153. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 104.90 and a beta of 0.84. The company has a 50-day simple moving average of $37.89 and a two-hundred day simple moving average of $45.15. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $63.57.

Analysts Set New Price Targets

A number of brokerages have recently commented on LIVN. The Goldman Sachs Group cut their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Barclays reduced their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday. Needham & Company LLC reissued a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Robert W. Baird raised their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Mizuho lowered their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $59.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.